Changes in ER, PR, HER2, and Their Association With Disease Outcome in Invasive Breast Carcinoma (IBC) Patients Post-Neo Adjuvant Chemotherapy (NAC) and Surgery
Open Access
- 5 June 2025
- journal article
- Published by SAGE Publications in Breast Cancer: Basic and Clinical Research
- Vol. 19
Abstract
Background: Estrogen-receptor (ER), progesterone-receptor (PR), and human epidermal growth factor-2 (HER2) are performed on pre-neoadjuvant chemotherapy (NAC) biopsies of invasive breast carcinoma (IBC). However, they are not done routinely on post-NAC IBC with residual tumor. Objectives: This study helps in understanding the effect of alteration in expression of ER, PR, and HER2 in pre and post NAC IBC with residual tumors in terms of disease outcome, such as disease-free survival (DFS) and overall survival (OS). Design: This was a Cohort study (Prospective and Retrospective Cohort). Methods: All newly diagnosed cases of IBC who had undergone surgery after NAC with pre-NAC biopsies available with residual tumors in the breast, from January 2017 to January 2020 were enrolled in the study (n = 174) and were followed up till July 2022. Results: There were 174 cases included in this study. Of the 174 cases, 77 (44%) ER+ cases turned −ve, 10 ER +ve cases remained +ve and 87(50%) cases which were ER−ve remained the same. 48(27%) of PR +ve cases turned −ve, 10 PR +ve cases remained +ve and 116 (67%) cases remained −ve. 64(36%) of HER2 +ve cases turned −ve, 4 (2%) of HER2 +ve cases remained +ve; whereas 103(59%) cases remained −ve. The cases with changes in ER and HER2 status from positive to negative showed a longer DFS and OS which was statistically significant. Conclusion: There is a change in the HR and HER2 status in cases of IBC with residual tumor post NAC and patients with changes in the receptor status post-NAC have a better OS and DFS than those whose receptor status do not show a change.Keywords
Funding Information
- Jawaharlal Institute Of Postgraduate Medical Education and Research
This publication has 27 references indexed in Scilit:
- Breast cancer histology and receptor status characterization in Asian Indian and Pakistani women in the U.S. - a SEER analysisBMC Cancer, 2010
- Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancerBritish Journal of Cancer, 2009
- Chemotherapy-induced tumor gene expression changes in human breast cancersPharmacogenetics and Genomics, 2009
- Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre- and post-neoadjuvant chemotherapyThe Breast, 2008
- Changes in and Prognostic Value of Hormone Receptor Status in a Series of Operable Breast Cancer Patients Treated with Neoadjuvant ChemotherapyThe Oncologist, 2007
- HER2/neu, p53, Ki67, and hormone receptors do not change during neoadjuvant chemotherapy in breast cancerVirchows Archiv, 2005
- Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline‐based neoadjuvant chemotherapy in patients with breast carcinomaCancer, 2002
- erbB-2, p53, and Efficacy of Adjuvant Therapy in Lymph Node-Positive Breast CancerJNCI: Journal of the National Cancer Institute, 1998
- Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.Journal of Clinical Oncology, 1996
- EFFECTS OF ADJUVANT CHEMOHORMONAL THERAPY ON THE OVARIAN AND ADRENAL-FUNCTION OF BREAST-CANCER PATIENTS1980